vir.bio (VIR) Short-Term Debt to Equity

vir.bio - graphic logo of issuer VIR

The financial stability of Vir Biotechnology, Inc. (VIR) is based on the development of hepatitis drugs, with the separate_debt_short_eq metric standing at 0.00. High barriers to entry are ensured by complex certification processes and immunology patents. This price action on GURU.Markets underscores the status of a tech leader investing in RNA interference and antibodies to combat dangerous infections.

Short-Term Debt to Equity Ratio: Vir Biotechnology Inc (VIR) for 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for vir.bio (VIR)

- stock quotes and analyst forecast:
Stock Price Vir Bio|VIR - Analyst Consensus Forecast
- market capitalization details:
Market Value Vir Biotechnology Inc|VIR - Value Adjusted for Debt and Cash
- balance sheet equity data:
Net Assets per Single Share Vir Biotechnology|VIR - Company Net Assets|Market Capitalization to Book Value Ratio vir.bio|VIR - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Vir Biotechnology, Inc.|VIR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Vir Biotechnology|VIR - Company Debts|Debts to Book Capitalization Vir Biotechnology Inc|VIR - Long-Term Debt Volume|Company Short-Term Debt Vir Biotechnology|Quick Liquidity Indicator vir.bio
- company profitability and valuation multiples indicators:
VIR - Net Profit
General company analysis:Vir Bio
Product sample of Vir Biotechnology Inc

Vir Biotechnology, Inc. (VIR) maintains independence from macroeconomic cycles and a substantial cash reserve, ensuring stable funding for long-term immunological research. By analyzing this chart of the short-term debt-to-equity ratio, an investor assesses the proportion of liabilities maturing within one year relative to equity, which confirms a low debt load and high resilience of the stock's market value to default risks.

Main competitors

Short-Term Debt to Capital GILD|Short-Term Debt to Capital Cidara Therapeutics Inc (CDTX)|Short-Term Debt to Equity Novavax, Inc. NVAX|Ratio of Short-Term Indebtedness to Capital CVAC|VALN - Short-Term Debt to Equity|SIGA Technologies Inc (SIGA) - Short-Term Debt to Equity Ratio|EBS: Short-Term Debt to Capital|Atea Corp (AVIR) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio IVVD|ENTA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio INO (Inovio)|Short-Term Debt to Equity HLVX (HilleVax Inc)|Short-Term Debt to Capital KLRS (Kalaris Therapeutics, Inc.)|Short-Term Debt to Capital Coefficient Dyadic International Inc (DYAI)|NNVC - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital TLPH (talphera.com)|COCP (Cocrystal Pharma) - Short-Term Debt to Equity Ratio|Traws Pharma (TRAW) - Short-Term Debt to Capital|Short-Term Debt to Equity Dogwood Therapeutics Inc.|Qualigen Corp (QLGN) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio ALVR (AlloVir, Inc.)|Short-Term Debt to Equity VBIV (vbivaccines.com)|Short-Term Debt to Capital VIRI (Virios Therapeutics, Inc.)|Short-Term Debt to Capital Coefficient Vaxart Inc. (VXRT)